PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
18.34%
Net income growth above 1.5x TRAW's 10.82%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-12.79%
Both reduce yoy D&A, with TRAW at -13.64%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
35.67%
Deferred tax of 35.67% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-6.19%
Both cut yoy SBC, with TRAW at -12.53%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
947.27%
Well above TRAW's 195.45% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
844.13%
AP growth well above TRAW's 406.12%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-18.50%
Negative yoy usage while TRAW is 129.29%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-6.19%
Both negative yoy, with TRAW at -57.89%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
46.02%
Operating cash flow growth 1.25-1.5x TRAW's 36.83%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
81.40%
CapEx growth of 81.40% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.69%
We reduce yoy other investing while TRAW is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
80.57%
We expand invests by 80.57% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-99.82%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.